ZA200110401B - Multiparticulate controlled release selective serotonin reuptake inhibitor formulations. - Google Patents

Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.

Info

Publication number
ZA200110401B
ZA200110401B ZA200110401A ZA200110401A ZA200110401B ZA 200110401 B ZA200110401 B ZA 200110401B ZA 200110401 A ZA200110401 A ZA 200110401A ZA 200110401 A ZA200110401 A ZA 200110401A ZA 200110401 B ZA200110401 B ZA 200110401B
Authority
ZA
South Africa
Prior art keywords
controlled release
serotonin reuptake
reuptake inhibitor
selective serotonin
inhibitor formulations
Prior art date
Application number
ZA200110401A
Other languages
English (en)
Inventor
Theresa Ann Jeary
Catherine Ann Morrissey
Paul Stark
Original Assignee
Elan Corp Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27620490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200110401(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Elan Corp Plc filed Critical Elan Corp Plc
Publication of ZA200110401B publication Critical patent/ZA200110401B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200110401A 1999-05-20 2001-12-19 Multiparticulate controlled release selective serotonin reuptake inhibitor formulations. ZA200110401B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IE19990406A IE990406A1 (en) 1999-05-20 1999-05-20 Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.

Publications (1)

Publication Number Publication Date
ZA200110401B true ZA200110401B (en) 2003-03-03

Family

ID=27620490

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200110401A ZA200110401B (en) 1999-05-20 2001-12-19 Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.

Country Status (4)

Country Link
US (2) US7465462B1 (xx)
IE (1) IE990406A1 (xx)
UA (1) UA74335C2 (xx)
ZA (1) ZA200110401B (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE990406A1 (en) * 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
US20060105036A1 (en) 2003-05-12 2006-05-18 Stephen Peroutka Threo-dops controlled release formulation
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
CA2598273A1 (en) * 2005-02-17 2006-08-24 Merck & Co., Inc. Method of treating atherosclerosis, dyslipidemias and related conditions
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
US20120064133A1 (en) * 2009-05-28 2012-03-15 Ishwar Chauhan Multiparticulate Controlled-Release Selective Serotonin Reuptake Inhibitor Formulations
CN102579406A (zh) * 2012-01-17 2012-07-18 广州科的信医药技术有限公司 一种盐酸氯米帕明缓释胶囊及其制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7503310A (nl) 1975-03-20 1976-09-22 Philips Nv Verbindingen met antidepressieve werking.
US4851228A (en) * 1984-06-20 1989-07-25 Merck & Co., Inc. Multiparticulate controlled porosity osmotic
US5271946A (en) * 1988-04-20 1993-12-21 Asta Pharma Aktiengesellschaft Controlled release azelastine-containing pharmaceutical compositions
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5958458A (en) * 1994-06-15 1999-09-28 Dumex-Alpharma A/S Pharmaceutical multiple unit particulate formulation in the form of coated cores
GB9514842D0 (en) 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
PE57198A1 (es) 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
HRP970493A2 (en) * 1996-09-23 1998-08-31 Wienman E. Phlips Oral delayed immediate release medical formulation and method for preparing the same
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US5910319A (en) 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
CN1475209A (zh) 1997-07-01 2004-02-18 �Ʒ� 舍曲林的缓释剂型
IL152330A0 (en) 1997-07-01 2003-05-29 Pfizer Sertraline salts and sustained-release dosage forms of sertraline
CN1277550A (zh) * 1997-09-11 2000-12-20 尼科梅德丹麦有限公司 非甾体抗炎药物(NSAIDs)的改进释放的复合型组合物
US6066339A (en) * 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
US5948440A (en) * 1997-12-17 1999-09-07 Ranbaxy Laboratories Limited Modified release matrix formulation of cefaclor and cephalexin
IE990406A1 (en) * 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
US6080736A (en) * 1999-10-27 2000-06-27 Janus Pharmaceuticals, Inc. Methods and compositions for treating and preventing anxiety and anxiety disorders using optically pure (R) tofisopam
US6458384B2 (en) * 2000-02-23 2002-10-01 Impetus Ag Pharmaceutical with predetermined activity profile
US6306436B1 (en) * 2000-04-28 2001-10-23 Teva Pharmaceuticals Usa, Inc. Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
US6482440B2 (en) * 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles

Also Published As

Publication number Publication date
UA74335C2 (uk) 2005-12-15
US20080206335A1 (en) 2008-08-28
IE990406A1 (en) 2000-12-27
US7465462B1 (en) 2008-12-16

Similar Documents

Publication Publication Date Title
HK1041347A1 (en) Head support mechanism.
MXPA03003235A (es) Formulaciones farmaceuticas de liberacion retrasada.
EG25095A (en) Phenyl-piperazines derivatives as serotonin reuptake inhibitors.
EG24742A (en) Vaccine composition.
MXPA03008807A (es) Derivados de ciclopropilindol como inhibidores selectivos de recaptacion de serotonina.
IL179379A0 (en) Multiparticulate modified release composition
EP1156812A4 (en) MULTIPARTICULAR FORMULATION
MXPA01005543A (es) Formulacion de liberacion controlada que consta de gnrh-ii.
MXPA02001919A (es) Fenilpiperazinas novedosas.
HK1149938A1 (en) P.gingivalis antigenic composition
IT1321100B1 (it) Dispositivo di asservimento per freno.
ZA200106683B (en) Method for the preparation of citalopram.
ZA200206699B (en) Method for the preparation of citalopram.
PL362982A1 (en) Benzothiophene derivative compounds, process for the preparation and use thereof
MXPA02008907A (es) Capsulas.
ZA200007548B (en) Matrix table enabling the prolonged release of trimetazidine after administration by the oral route.
HUP0201884A3 (en) Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
MXPA03006792A (es) Agente de aromatizacion.
HK1052924A1 (en) O-substituted 6-methyl-tramadol derivatives.
ZA200206151B (en) Substituted amionomethyl-phenyl-cyclohexane derivatives.
ZA200109206B (en) Preparation of substituted piperidin-4-ones.
ZA200110401B (en) Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
MXPA03004071A (es) Formulaciones de combinacion de adyuvantes.
MXPA01010701A (es) Vacuna.
PH12001001922B1 (en) Crystalline therapeutic agent.